INCY News and Press, Incyte Corporation From 06/25/20

Oncolytics Biotech (NASDAQ: ONCY ) announces a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. More news on: Oncolytics Biotech Inc., Incyte Corporation, Healthcare stocks news, Read more ...

Novartis (NYSE: NVS) and Teva Pharmaceutical (NYSE: TEVA) are two very well-known names in the big pharma space. Shares for both companies have recovered well since their lows during the coronavirus crash. Novartis is a popular high-growth stock, and Teva's mouthwateringly cheap share pr...

Incyte (Nasdaq:INCY) has updated its presentation time at the following investor conference: JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT). The presentation at the BMO Prescriptions for Success Healthcare Conference (Vi...

- Content highlights Incyte’s approach to business and environmental sustainability - Inaugural Sustainable Accounting Standards Board (SASB) Summary now available Incyte (Nasdaq:INCY) today announced that a new Global Responsibility section has been launched as part of ...

Enrollment is underway in a Phase 3 clinical trial, COV-BARRIER , evaluating Eli Lilly's (NYSE: LLY ) Olumiant (baricitinib), an oral JAK1/JAK2 inhibitor licensed from Incyte (NASDAQ: INCY ), in hospitalized COVID-19 patients including those with at least one elevated marker of inflammat...

The following slide deck was published by Incyte Corporation in conjunction with this Read more ...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

"One of the most attractive growth stories in biotech," says analyst Salveen Richter, lifting the price target on Seattle Genetics (NASDAQ: SGEN ) to a Street-high $246 (nearly  60% upside ), and adding to the bank's Conviction List. More news on: Seattle Genetics, Inc., Incyte C...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...